This panel has been developed for the evaluation of diverse BC aspects, including BC subtyping (luminal A/B, HER2-enriched, basal-like, triple-negative), expression of BC receptors and signaling (ESR1, PGR, ERBB2, AR, PTEN, CDK4, CDK6), mutational content (HRD, BRCA, P53), markers for tumor proliferation, apoptosis and differentiation (FOXA1, SOX2), cell adhesion (claudin), and immunity (chemokines, TGF-β, PD-1). This evidence concerns the gene ERBB2 and neoplasm.